Michael Vincent Mcconnell, MD
Cardiovascular Disease (Cardiology) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mcconnell’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$7,879
Medicare paid this office $7,879 for 82 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 28 | $3,102 | $82 |
| Short return visit (20+ min) | 29 | $1,555 | $43 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 19 | $1,112 | $59 |
Who their Medicare patients are
82 Original Medicare patients in 2024. Average age 77 · Women 35% · Also on Medicaid 29% · Health risk score 1.48. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 54% · Diabetes 44% · Chronic kidney disease 30% · Heart failure 27% · Cancer 27% · Atrial fibrillation 27%.
The office billed $35,871, Medicare allowed $11,151 and paid $7,879; for 128 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 82 | 128 | 77 | 1.48 | $35,871 | $7,879 |
| 2023 | 70 | 102 | 77 | 1.25 | $23,148 | $6,276 |
| 2022 | 90 | 127 | 75 | 1.45 | $37,184 | $7,567 |
| 2021 | 85 | 120 | 75 | 1.23 | $42,530 | $7,356 |
| 2020 | 108 | 153 | 74 | 1.79 | $56,608 | $7,764 |
| 2019 | 79 | 135 | 75 | 1.28 | $22,910 | $7,000 |
| 2018 | 240 | 367 | 73 | 2.11 | $71,703 | $17,689 |
| 2017 | 141 | 200 | 75 | 2.06 | $39,459 | $10,217 |
| 2016 | 388 | 537 | 74 | 2.22 | $121,993 | $25,833 |
| 2015 | 1,031 | 1,611 | 73 | 2.08 | $378,076 | $75,284 |
| 2014 | 969 | 1,443 | 74 | 1.92 | $315,870 | $58,058 |
| 2013 | 1,150 | 1,883 | 73 | 1.75 | $410,908 | $75,937 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 34 | $3,181 | $78 |
| Short return visit (20+ min) | 27 | $1,435 | $45 |
2022: 3 services
| Return visit (30+ min) | 33 | $2,735 | $76 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 27 | $1,402 | $52 |
| Short return visit (20+ min) | 24 | $1,383 | $49 |
2021: 2 services
| Return visit (30+ min) | 29 | $2,768 | $75 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 34 | $1,878 | $55 |
2020: 2 services
| Return visit (30+ min) | 38 | $2,804 | $58 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 44 | $2,435 | $55 |
2019: 2 services
| Return visit (30+ min) | 59 | $5,187 | $62 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 16 | $880 | $55 |
2018: 8 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 143 | $8,877 | $61 |
| Return visit (30+ min) | 65 | $5,547 | $59 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 22 | $1,293 | $59 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 20 | $362 | $18 |
| Ultrasound of heart, follow-up | 14 | $303 | $22 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 20 | $243 | $12 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $200 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 15 | $41 | $3 |
2017: 2 services
| Return visit (30+ min) | 68 | $6,081 | $60 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 66 | $3,294 | $50 |
2016: 10 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 268 | $14,431 | $52 |
| Return visit (30+ min) | 87 | $8,211 | $60 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 17 | $807 | $47 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 11 | $630 | $57 |
| Ultrasound of heart, follow-up | 15 | $372 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 17 | $280 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 17 | $183 | $11 |
| Ultrasound of heart blood flow, valves and chambers | 11 | $133 | $12 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 11 | $79 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $32 | $2 |
2015: 11 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 696 | $40,809 | $54 |
| Return visit (30+ min) | 85 | $8,644 | $62 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 122 | $7,456 | $61 |
| Ultrasound of heart with probe in esophagus, with report | 41 | $4,370 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $2,456 | $65 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 117 | $2,266 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 142 | $1,785 | $13 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 34 | $818 | $24 |
| Ultrasound of heart blood flow, valves and chambers | 46 | $766 | $17 |
| Ultrasound of heart, follow-up | 15 | $349 | $23 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 81 | $244 | $3 |
2014: 10 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 603 | $32,518 | $52 |
| Return visit (30+ min) | 100 | $9,575 | $61 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 103 | $5,875 | $57 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 261 | $3,320 | $13 |
| Ultrasound of heart with probe in esophagus, with report | 24 | $2,346 | $94 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 99 | $1,787 | $18 |
| Ultrasound of heart blood flow, valves and chambers | 48 | $747 | $16 |
| Ultrasound of heart, follow-up | 20 | $428 | $21 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 67 | $200 | $3 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 16 | $96 | $6 |
2013: 16 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 603 | $31,995 | $51 |
| Return visit (30+ min) | 90 | $10,066 | $59 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 150 | $8,581 | $57 |
| Ultrasound of heart with probe in esophagus, with report | 47 | $4,109 | $86 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 262 | $3,250 | $12 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,194 | $118 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 143 | $2,589 | $18 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 111 | $2,474 | $22 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $2,172 | $62 |
| New patient visit (45+ min) | 18 | $1,804 | $100 |
| Ultrasound of heart blood flow, valves and chambers | 76 | $1,144 | $15 |
| Hospital discharge day management, 30 minutes or less | 14 | $893 | $64 |
| Ultrasound of heart, follow-up | 18 | $422 | $22 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 115 | $352 | $3 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 15 | $304 | $20 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $75 | $6 |
Medicaid work
$947 in 2018
Medicaid paid $947 for 13 billed services this clinician did in 2018, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 13 | $947 |
| 2018 | 13 | 1 | 13 | $947 |
Drugs they prescribed that Part D paid
$59,994
Pharmacies billed $59,994 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 425) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
376 generic and 49 brand-name prescriptions · $59,994 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 22 | $25,051 | $1,139 |
| Ezetimibe | 40 | $1,449 | $36 |
| Rosuvastatin | 17 | $608 | $36 |
| Atorvastatin | 88 | $595 | $7 |
| Metoprolol | 36 | $329 | $9 |
See all 12 drugs
| Eliquis | 22 | $25,051 | $1,139 |
| Ezetimibe | 40 | $1,449 | $36 |
| Rosuvastatin | 17 | $608 | $36 |
| Atorvastatin | 88 | $595 | $7 |
| Metoprolol | 36 | $329 | $9 |
| Carvedilol | 18 | $269 | $15 |
| Amlodipine Besylate | 39 | $252 | $6 |
| Losartan | 19 | $217 | $11 |
| Simvastatin | 12 | $147 | $12 |
| Metoprolol | 13 | $98 | $8 |
| Hydrochlorothiazide | 12 | $92 | $8 |
| Lisinopril | 24 | $78 | $3 |
Year by year
| 2024 | 425 | 43 | 0% (0) | 12% | $59,994 |
| 2023 | 416 | 44 | 0% (0) | 10% | $45,228 |
| 2022 | 385 | 40 | 0% (0) | 16% | $56,250 |
| 2021 | 334 | 39 | 0% (0) | 18% | $52,832 |
| 2020 | 443 | 45 | 0% (0) | 15% | $53,848 |
| 2019 | 448 | 50 | 0% (0) | 15% | $52,173 |
| 2018 | 499 | 59 | 0% (0) | 13% | $54,687 |
| 2017 | 632 | 72 | 0% (0) | 19% | $62,384 |
| 2016 | 829 | 80 | 0% (0) | 18% | $64,444 |
| 2015 | 846 | 96 | 0% (0) | 23% | $58,610 |
| 2014 | 883 | 89 | 0% (0) | 21% | $50,486 |
| 2013 | 896 | 84 | 0% (0) | 23% | $42,720 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Eliquis | 18 | $18,105 | $1,006 |
| Ezetimibe | 38 | $1,798 | $47 |
| Atorvastatin | 82 | $927 | $11 |
| Metoprolol | 18 | $483 | $27 |
| Carvedilol | 27 | $431 | $16 |
| Metoprolol | 29 | $403 | $14 |
| Rosuvastatin | 15 | $393 | $26 |
| Amlodipine Besylate | 39 | $326 | $8 |
| Lisinopril | 27 | $278 | $10 |
| Losartan | 15 | $142 | $9 |
| Hydrochlorothiazide | 17 | $113 | $7 |
| Simvastatin | 14 | $103 | $7 |
2022: 13 drugs
| Eliquis | 21 | $22,141 | $1,054 |
| Xarelto | 14 | $13,263 | $947 |
| Praluent | 14 | $7,569 | $541 |
| Ezetimibe | 16 | $1,329 | $83 |
| Atorvastatin | 77 | $772 | $10 |
| Carvedilol | 22 | $505 | $23 |
| Rosuvastatin | 15 | $428 | $29 |
| Metoprolol | 22 | $244 | $11 |
| Amlodipine Besylate | 39 | $188 | $5 |
| Hydrochlorothiazide | 22 | $181 | $8 |
| Lisinopril | 23 | $150 | $7 |
| Losartan | 11 | $115 | $10 |
| Simvastatin | 15 | $104 | $7 |
2021: 12 drugs
| Eliquis | 19 | $20,604 | $1,084 |
| Xarelto | 16 | $11,429 | $714 |
| Praluent | 19 | $8,788 | $463 |
| Ezetimibe | 18 | $975 | $54 |
| Atorvastatin | 66 | $903 | $14 |
| Carvedilol | 21 | $403 | $19 |
| Hydrochlorothiazide | 26 | $251 | $10 |
| Metoprolol | 25 | $242 | $10 |
| Losartan | 11 | $240 | $22 |
| Simvastatin | 11 | $119 | $11 |
| Amlodipine Besylate | 24 | $115 | $5 |
| Lisinopril | 17 | $91 | $5 |
2020: 12 drugs
| Eliquis | 18 | $18,998 | $1,055 |
| Xarelto | 24 | $11,737 | $489 |
| Praluent | 12 | $5,708 | $476 |
| Atorvastatin | 81 | $1,739 | $21 |
| Ezetimibe | 31 | $1,629 | $53 |
| Rosuvastatin | 17 | $1,355 | $80 |
| Carvedilol | 36 | $596 | $17 |
| Amlodipine Besylate | 35 | $321 | $9 |
| Metoprolol | 23 | $292 | $13 |
| Hydrochlorothiazide | 32 | $278 | $9 |
| Lisinopril | 31 | $257 | $8 |
| Losartan | 13 | $145 | $11 |
2019: 14 drugs
| Eliquis | 19 | $15,222 | $801 |
| Xarelto | 20 | $11,899 | $595 |
| Praluent | 12 | $7,948 | $662 |
| Atorvastatin | 104 | $2,351 | $23 |
| Ezetimibe | 35 | $1,881 | $54 |
| Rosuvastatin | 16 | $1,647 | $103 |
| Carvedilol | 35 | $584 | $17 |
| Diltiazem 24hr Er (Cd) | 11 | $416 | $38 |
| Hydrochlorothiazide | 34 | $415 | $12 |
| Metoprolol | 17 | $339 | $20 |
| Lisinopril | 30 | $311 | $10 |
| Amlodipine Besylate | 27 | $233 | $9 |
| Losartan | 13 | $207 | $16 |
| Simvastatin | 16 | $185 | $12 |
2018: 16 drugs
| Praluent | 11 | $12,491 | $1,136 |
| Xarelto | 20 | $12,486 | $624 |
| Eliquis | 13 | $6,674 | $513 |
| Ezetimibe | 32 | $5,053 | $158 |
| Atorvastatin | 113 | $2,514 | $22 |
| Rosuvastatin | 11 | $979 | $89 |
| Metoprolol | 27 | $905 | $34 |
| Carvedilol | 43 | $510 | $12 |
| Clopidogrel | 14 | $471 | $34 |
| Hydrochlorothiazide | 26 | $327 | $13 |
| Diltiazem 24hr Er (Cd) | 12 | $272 | $23 |
| Lisinopril | 27 | $250 | $9 |
| Amlodipine Besylate | 37 | $237 | $6 |
| Losartan | 25 | $234 | $9 |
| Simvastatin | 19 | $133 | $7 |
| Spironolactone | 16 | $100 | $6 |
2017: 19 drugs
| Zetia | 17 | $14,914 | $877 |
| Xarelto | 18 | $12,297 | $683 |
| Eliquis | 17 | $10,530 | $619 |
| Pradaxa | 14 | $5,715 | $408 |
| Atorvastatin | 143 | $3,103 | $22 |
| Ezetimibe | 11 | $3,052 | $277 |
| Rosuvastatin | 11 | $1,015 | $92 |
| Clopidogrel | 25 | $494 | $20 |
| Amlodipine Besylate | 51 | $420 | $8 |
| Lisinopril | 26 | $402 | $15 |
| Carvedilol | 53 | $397 | $7 |
| Diltiazem 24hr Er | 13 | $295 | $23 |
| Hydrochlorothiazide | 32 | $282 | $9 |
| Metoprolol | 17 | $270 | $16 |
| Losartan | 18 | $167 | $9 |
| Venlafaxine Hcl Er | 14 | $108 | $8 |
| Spironolactone | 14 | $82 | $6 |
| Furosemide | 29 | $63 | $2 |
| Simvastatin | 12 | $59 | $5 |
2016: 24 drugs
| Zetia | 36 | $16,343 | $454 |
| Pradaxa | 15 | $8,043 | $536 |
| Xarelto | 16 | $7,783 | $486 |
| Aggrenox | 11 | $5,110 | $465 |
| Atorvastatin | 177 | $3,748 | $21 |
| Rosuvastatin | 11 | $1,246 | $113 |
| Carvedilol | 71 | $562 | $8 |
| Valsartan | 11 | $510 | $46 |
| Clopidogrel | 24 | $509 | $21 |
| Diltiazem 24hr Er | 13 | $490 | $38 |
| Metoprolol | 18 | $471 | $26 |
| Amlodipine Besylate | 76 | $455 | $6 |
| Amiodarone | 13 | $351 | $27 |
| Warfarin | 14 | $348 | $25 |
| Fenofibrate | 11 | $308 | $28 |
| Losartan | 26 | $283 | $11 |
| Hydrochlorothiazide | 20 | $238 | $12 |
| Lisinopril | 29 | $227 | $8 |
| Spironolactone | 23 | $142 | $6 |
| Triamterene-Hydrochlorothiazid | 12 | $83 | $7 |
| Furosemide | 27 | $78 | $3 |
| Metoprolol | 18 | $66 | $4 |
| Clonidine | 16 | $46 | $3 |
| Omeprazole | 12 | $29 | $2 |
2015: 22 drugs
| Zetia | 26 | $10,087 | $388 |
| Pradaxa | 14 | $7,421 | $530 |
| Crestor | 17 | $4,851 | $285 |
| Aggrenox | 11 | $4,406 | $401 |
| Atorvastatin | 196 | $4,061 | $21 |
| Xarelto | 12 | $3,963 | $330 |
| Fenofibrate | 13 | $930 | $72 |
| Metoprolol | 21 | $658 | $31 |
| Warfarin | 22 | $577 | $26 |
| Amlodipine Besylate | 73 | $554 | $8 |
| Diltiazem 24hr Er | 12 | $515 | $43 |
| Carvedilol | 56 | $506 | $9 |
| Digoxin | 13 | $355 | $27 |
| Losartan | 39 | $326 | $8 |
| Clopidogrel | 24 | $309 | $13 |
| Lisinopril | 38 | $292 | $8 |
| Simvastatin | 23 | $263 | $11 |
| Hydrochlorothiazide | 16 | $189 | $12 |
| Pantoprazole | 12 | $169 | $14 |
| Metoprolol | 26 | $142 | $5 |
| Clonidine | 11 | $49 | $4 |
| Furosemide | 15 | $35 | $2 |
2014: 18 drugs
| Pradaxa | 18 | $10,221 | $568 |
| Zetia | 13 | $4,119 | $317 |
| Atorvastatin | 179 | $3,818 | $21 |
| Crestor | 14 | $3,702 | $264 |
| Aggrenox | 11 | $3,616 | $329 |
| Fenofibrate | 13 | $1,084 | $83 |
| Metoprolol | 22 | $868 | $39 |
| Amlodipine Besylate | 73 | $748 | $10 |
| Carvedilol | 59 | $723 | $12 |
| Digoxin | 18 | $538 | $30 |
| Clopidogrel | 43 | $533 | $12 |
| Diltiazem 24hr Er | 14 | $455 | $33 |
| Simvastatin | 46 | $450 | $10 |
| Lisinopril | 58 | $444 | $8 |
| Losartan | 43 | $437 | $10 |
| Amiodarone | 18 | $321 | $18 |
| Warfarin | 16 | $259 | $16 |
| Hydrochlorothiazide | 20 | $137 | $7 |
2013: 23 drugs
| Zetia | 30 | $8,353 | $278 |
| Pradaxa | 19 | $8,332 | $439 |
| Atorvastatin | 124 | $4,651 | $38 |
| Clopidogrel | 26 | $1,709 | $66 |
| Metoprolol | 32 | $1,599 | $50 |
| Valsartan-Hydrochlorothiazide | 11 | $1,161 | $106 |
| Amlodipine Besylate | 79 | $993 | $13 |
| Losartan | 52 | $888 | $17 |
| Fenofibrate | 12 | $809 | $67 |
| Prevalite | 12 | $750 | $63 |
| Carvedilol | 63 | $735 | $12 |
| Diltiazem 24hr Er | 20 | $687 | $34 |
| Simvastatin | 70 | $594 | $8 |
| Lisinopril | 58 | $473 | $8 |
| Ramipril | 13 | $402 | $31 |
| Diltiazem 24hr Cd | 11 | $311 | $28 |
| Metformin | 12 | $289 | $24 |
| Hydrochlorothiazide | 24 | $246 | $10 |
| Amiodarone | 18 | $246 | $14 |
| Atenolol | 11 | $128 | $12 |
| Digoxin | 12 | $97 | $8 |
| Lovastatin | 12 | $77 | $6 |
| Losartan-Hydrochlorothiazide | 12 | $73 | $6 |
Money from drug and device companies
$62 in 2023
| 2023 | 1 | 2 | None | $62 |
| 2021 | 1 | 1 | None | $2,399 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Integra LifeSciences | Durasorb Monofilament Mesh | $62 | 2 payments
|
See all 2 published payments
| Integra LifeSciences | Meals · 2023-05-11 | Durasorb Monofilament Mesh | $35 |
| Integra LifeSciences | Meals · 2023-04-28 | Durasorb Monofilament Mesh | $27 |
See earlier years (2021)
2021: $2,399
| Butterfly Network | Butterfly Iq | $2,399 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1508906728
- Licence
- CA G084768
- Trained
- Stanford University School of Medicine, 1990
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-07
- NPI last updated
- 2024-04-23
- NPI record certified
- 2024-04-23
This is when the NPI record was last certified, not a medical board exam.